Better Access to Liver Cancer Medicines
Non-alcoholic fatty liver disease (NAFLD) study
Non-alcoholic fatty liver disease (NAFLD) – a condition in which fat accumulates in the liver…Read Article
Five common liver cancer myths
In honour of World Cancer Day on the 4th of February, Hepatitis Queensland is busting…Read Article
Alcohol tips during the festive season
The holiday season usually means getting together with family and friends to celebrate and be…Read Article
Australians living with liver cancer will soon have new treatment options with changes to the Pharmaceutical Benefits Scheme (PBS) coming into effect.
The changes include better access to treatments for patients with advanced unresectable hepatocellular carcinoma. Unresectable hepatocellular carcinoma is the most common form of liver cancer, which often occurs in people with other chronic liver diseases. It also has one of the lowest survival rates of all cancer types.
From 1 November, more than 500 patients per year could benefit from PBS listing of this treatment, which would otherwise cost more than $170,000 per course. Australia will be the first country in the world to have this combination treatment publically funded for this type of liver cancer.